The Best Small-Cap Stocks to Buy Now
Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.


The second half of 2025 could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps performed through the first half of the year. After all, small caps as an asset class have been a dud. They went nowhere as mega-cap stocks pushed the broader market to record highs.
To recap: the broader S&P 500 gained almost 8.6% on a price basis through early August, while the tech-heavy Nasdaq Composite rose more than 11%. The blue-chip Dow Jones Industrial Average rose just 3.4%, hurt partly by its price-weighted construction.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But while select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) helped drive the market's gains, small caps – which tend to be more sensitive to the economic cycle and interest rates – traded sideways.
Indeed, the small-cap benchmark Russell 2000 Index – struggling to stay positive for months – was slightly negative through the first eight months of the year.
If there is a sliver of a silver lining to the Russell 2000's underperformance, it's that small caps are now trading at bargain basement prices.
"As the premium on large caps continues to expand, small-cap equities become increasingly attractive on a relative basis," writes Jeff Buchbinder, chief equity strategist for LPL Financial. "Their lower valuations may signal undiscovered value or underappreciated growth potential, particularly in sectors poised to benefit from domestic policy tailwinds."
And with the Federal Reserve expected to enact several incremental cuts to the federal funds rate before year-end, small caps should have at least one catalyst on the horizon.
Our methodology for finding the best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.
Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.
Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.
That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Analysts' consensus recommendation score | Subsector | Analysts' consensus recommendation |
---|---|---|---|
Spyre Therapeutics (SYRE) | 1.14 | Biotechnology | Strong Buy |
Denali Therapeutics (DNLI) | 1.16 | Biotechnology | Strong Buy |
Waystar Holding (WAY) | 1.19 | Health Care Technology | Strong Buy |
Xenon Pharmaceuticals (XENE) | 1.21 | Biotechnology | Strong Buy |
Genius Sports (GENI) | 1.22 | Casinos & Gaming | Strong Buy |
Janux Therapeutics (JANX) | 1.22 | Biotechnology | Strong Buy |
Axsome Therapeutics (AXSM) | 1.25 | Pharmaceuticals | Strong Buy |
Wave Life Sciences (WVE) | 1.27 | Pharmaceuticals | Strong Buy |
Kymera Therapeutics (KYMR) | 1.27 | Biotechnology | Strong Buy |
Riot Platforms (RIOT) | 1.28 | Application Software | Strong Buy |
Avidity Biosciences (RNA) | 1.28 | Biotechnology | Strong Buy |
Braze (BRZE) | 1.30 | Application Software | Strong Buy |
Biohaven (BHVN) | 1.33 | Biotechnology | Strong Buy |
Guardant Health (GH) | 1.35 | Health Care Services | Strong Buy |
BridgeBio Pharma (BBIO) | 1.37 | Biotechnology | Strong Buy |
Essential Properties Realty Trust (EPRT) | 1.37 | Diversified REITs | Strong Buy |
Arcellx (ACLX) | 1.39 | Biotechnology | Strong Buy |
Privia Health Group (PRVA) | 1.40 | Health Care Services | Strong Buy |
IDEAYA Biosciences (IDYA) | 1.42 | Biotechnology | Strong Buy |
NetSTREIT (NTST) | 1.50 | Retail REITs | Strong Buy |
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
The Ultimate Cruise Packing List for Retirees
Ready to set sail on your dream cruise? Here’s a no-fuss packing list tailored for older travelers to keep your trip stress-free.
-
Extended payment plans can help ease the sting of a big-ticket purchase. But beware of costly missteps that can add to your price.
Don't Make These 'Buy Now, Pay Later' Mistakes
-
I'm a Real Estate Investing Pro: This 1031 Exchange Strategy Can Triple Your Cash Flow
Savvy investors can use 1031 exchanges to unlock value by moving capital across markets in a play called geographic arbitrage. These tax implications can make or break the strategy.
-
I'm an Insurance Pro: Everyone Needs to Prepare for Earthquakes, Even if You Don't Live Near a Fault Line
Here are my tips for what to do before, during and after an earthquake. The more prepared you are, the more you'll be able to keep your wits about you if it happens.
-
Stocks Retreat as Shutdown Continues: Stock Market Today
While the main indexes closed lower today, Delta and PepsiCo gained ground on encouraging earnings reports.
-
Where There's a Will, There's a Way Your Assets Will Be Distributed as You Wish
Your will is the backbone of a strong, adaptable estate plan that ensures what you leave behind goes to your selected beneficiaries. Without a will, state laws determine who gets your assets.
-
I'm a Financial Adviser: This Is What You're Really Losing if You Cut Back on Your 401(k) Contributions
Missing out on the benefits of the employer match and compounding growth could force you to work longer and lower your standard of living in retirement. Here are some alternative options.
-
S&P 500 Hits New Highs as Rally Resumes: Stock Market Today
Tech stocks were the biggest gainers on Wall Street today, with Nvidia and Dell making notable moves.
-
Should You Buy Gold as It Tops $4,000? Here's What the Experts Say
Rate cuts, a weak dollar and macro uncertainty have helped create a "perfect storm" for gold this year. Should investors add exposure or is it too late to buy?
-
Preferred Bank Stocks: The Investment Retirees (and Others) May Be Missing Out On
Most large banks issue preferred stocks that pay out fixed dividends, often with higher yields than bonds. Should you make room for them in your portfolio?